Your browser doesn't support javascript.
Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis.
Yassin, Ahmed; Ghzawi, Ansam; Al-Mistarehi, Abdel-Hameed; El-Salem, Khalid; Y Benmelouka, Amira; M Sherif, Ahmed; BenhadjDahman, Nesrine; AlAdamat, Nameer; Jemel, Amine; Negida, Ahmed; Abdelmonem, Mohamed.
  • Yassin A; Division of Neurology, Department of Neurosciences, Faculty of Medicine, Jordan University of Science & Technology, Irbid, Jordan.
  • Ghzawi A; Faculty of Medicine, Yarmouk University, Irbid, Jordan.
  • Al-Mistarehi AH; Department of Public Health & Family Medicine, Jordan University of Science & Technology, Irbid, Jordan.
  • El-Salem K; Division of Neurology, Department of Neurosciences, Faculty of Medicine, Jordan University of Science & Technology, Irbid, Jordan.
  • Y Benmelouka A; University of Algiers, Algeria.
  • M Sherif A; Faculty of Human Medicine, Zagazig University, Sharkia, Egypt.
  • BenhadjDahman N; Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia.
  • AlAdamat N; Department of Internal Medicine, Faculty of Medicine, Jordan University of Science & Technology, Irbid, Jordan.
  • Jemel A; Department of Thoracic & Cardiovascular Surgery, Abderrahmen Mami Hospital, Tunisia.
  • Negida A; Faculty of Human Medicine, Zagazig University, Sharkia, Egypt.
  • Abdelmonem M; School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, Hampshire, England.
Future Sci OA ; 7(7): FSO713, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1232494
ABSTRACT

OBJECTIVE:

To describe the mortality difference between acute ischemic stroke (AIS) and non-AIS groups within COVID-19 patients. MATERIALS &

METHODS:

We included observational studies through September 2020 that categorized COVID-19 patients into two groups (with and without AIS).

RESULTS:

Eight studies with a total sample size of 19,399 COVID-19 patients were included. The pooled risk difference showed that patients with COVID-19 who developed AIS had significantly higher mortality than those without AIS by a risk difference of 24% (95% CI 0.10-0.39; p = 0.001). In two studies, the COVID-19+AIS group had significantly higher lymphocytes, procalcitonin and creatinine levels.

CONCLUSION:

Developing AIS significantly adds to the mortality of COVID-19. Timely interventions to manage those patients are strongly recommended.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Language: English Journal: Future Sci OA Year: 2021 Document Type: Article Affiliation country: Fsoa-2021-0036

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Language: English Journal: Future Sci OA Year: 2021 Document Type: Article Affiliation country: Fsoa-2021-0036